文献速递免疫规划传染病防控与疫情报告

重组天花病毒天坛株鼻内免疫诱导抗埃博拉系统与黏膜中和抗体

Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
PubMed 文献 · Vaccine · 2019-05-07

本研究构建了以天花病毒天坛株(VV)为载体、替换ha基因表达扎伊尔型埃博拉病毒(EBOV)gp的重组疫苗VV-Egp,经鼻内免疫BALB/c小鼠后评估免疫应答。结果显示VV-Egp诱导了针对EBOV的高水平中和血清IgG和IgA、大量GP特异性IFN-γ分泌淋巴细胞,以及鼻洗液中sIgA和阴道洗液中sIgA与IgG的黏膜中和抗体,提示该重组病毒可作为黏膜疫苗开发的通用平台。

要点

  • 重组VV-Egp鼻内免疫小鼠诱导高水平抗EBOV中和血清IgG和IgA。
  • 免疫后产生大量GP特异性IFN-γ分泌淋巴细胞。
  • 鼻洗液sIgA和阴道洗液sIgA、IgG均具EBOV GP特异性中和活性。

核心结论

  • 以VV天坛株为载体的重组VV-Egp经鼻内免疫可同时诱导系统性体液和细胞免疫以及黏膜中和抗体。

研究设计与样本

  • 构建替换VV ha基因表达EBOV gp的重组病毒VV-Egp,在BALB/c小鼠模型中进行鼻内免疫并评估免疫应答。

主要发现

  • VV-Egp鼻内免疫诱导高水平抗EBOV中和血清IgG和IgA。
  • 免疫后产生大量GP特异性IFN-γ分泌淋巴细胞。
  • 鼻洗液和阴道洗液中检测到EBOV GP特异性中和sIgA,阴道洗液还含特异性IgG。

临床怎么用

  • 提示重组VV载体鼻内接种可作为黏膜疫苗开发的可替换平台策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accumulating literature revealed that human mucosa was likely one of the important routes for EBOV attachment and further infection. Therefore inducing effective mucosal immune responses play key role in preventing the virus infection. Vaccinia virus Tiantan strain (VV) was a remarkably attenuated poxvirus, which has been broadly exploited as a multifunctional vector during the development of genetically recombinant vaccine and cancer therapeutic agent. In this study, we generated a recombinant VV harboring EBOV gp (VV-Egp) that was used to immunize mice, followed by assessing immune responses, particularly the mucosal immune responses to EBOV GP. A stable and further attenuated VV-Egp, in which the VV ha gene was replaced with the EBOV gp, was generated. In BALB/c mouse model, intranasal immunization with VV-Egp elicited robust humoral and cellular immune responses, including high level of neutralizing serum IgG and IgA against EBOV, and a large amount of GP-specific IFN-γ secreting lymphocytes. More importantly, EBOV GP-specific neutralizing secreted IgA (sIgA) in nasal wash and both sIgA and IgG in vaginal wash were induced. In summary, immunization with a safe and stable recombinant VV carrying a single EBOV gp conferred robust systemic immune response and mucosal neutralizing antibodies, indicating that the recombinant virus could be utilized as a viral vector for plug-and-play universal platform in mucosal vaccine development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xie L, Zai J, Yi K, et al. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice. Vaccine. 2019. PMID: 31076161. doi:10.1016/j.vaccine.2019.04.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。